— Know what they know.
Not Investment Advice

ALLO NASDAQ

Allogene Therapeutics, Inc.
1W: -8.4% 1M: -18.0% 3M: -4.4% YTD: +45.2% 1Y: +69.0% 3Y: -68.0% 5Y: -92.9%
$2.00
+0.04 (+2.04%)
After Hours: $2.02 (+0.02, +0.75%)
Weekly Expected Move ±8.1%
$2 $2 $2 $2 $2
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 29 · $487.7M mcap · 162M float · 5.86% daily turnover · Short 55% of daily vol

Cash Flow Trends

Operating Cash Flow
-$149M +25.5% ▲
Capital Expenditures
$386K +44.4% ▲
5Y CAGR: -64.2%
Free Cash Flow
-$150M +25.6% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$24M -196.5% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$257M-$333M-$327M-$258M-$191M
Depreciation & Amort.$10M$14M$14M$14M$12M
Stock-Based Comp.$81M$84M$66M$52M$38M
Change in Working Capital-$32M$4M-$15M-$25M-$11M
Other Non-Cash Items$3M$2M$25M$16M$3M
Operating Cash Flow-$185M-$221M-$238M-$200M-$149M
— Investing Activities —
Capital Expenditures-$21M-$5M-$2M-$694K-$386K
Acquisitions (Net)-$18M-$111M$0$0$0
Investment Purchases-$526M-$248M-$439M-$361M-$138M
Investment Sales$728M$359M$603M$438M$234M
Other Investing$0$111M$0$0$0
Investing Cash Flow$164M$106M$163M$76M$96M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$0$0$5M$2M$7M
Financing Cash Flow$12M$3M$96M$117M$30M
Net Change in Cash-$9M-$111M$21M-$8M-$24M
Cash End of Period$184M$72M$93M$86M$62M
Free Cash Flow-$206M-$226M-$239M-$201M-$150M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms